J&J surpasses Wall St forecasts with robust drug sales before Stelara rivalry

Johnson & Johnson Exceeds Q2 Expectations Despite Challenges

Johnson & Johnson (J&J) reported better-than-expected financial results for the second quarter, driven largely by robust performances from its pharmaceutical sector, notably cancer treatment Darzalex and the psoriasis drug Stelara. Stelara, a long-term revenue booster, is anticipated to generate more than $10 billion in sales this year. However, its sales may decline to approximately $7 billion by 2025, coinciding with the anticipated launch of up to six biosimilar versions in the U.S.

J&J's shares rose by nearly 3% to $155.4 in early trading. Chief Financial Officer Joe Wolk mentioned plans to finalize contracts within three months concerning U.S. insurance coverage for Stelara in 2025. Despite pending competition from biosimilars, J&J remains optimistic about growth in its pharmaceutical business.

For Q2, Stelara sales increased by 3.1% to $2.89 billion, surpassing analysts' estimates of $2.77 billion. Similarly, sales of Darzalex saw an 18.4% rise to $2.88 billion, slightly exceeding estimates of $2.86 billion. Wolk indicated that growth in the company's pharmaceuticals sector may slow down in the latter half of the year as Stelara biosimilars are introduced to the European market.

J&J's total revenue for the quarter reached $22.4 billion, outpacing the consensus estimate of $22.3 billion. Adjusted earnings came in at $2.82 per share, exceeding expectations of $2.70 per share. The company adjusted its full-year sales forecast to between $89.2 billion and $89.6 billion, up from a previous range of $88.7 billion to $89.1 billion. Conversely, the annual per-share forecast was lowered to a range between $10 and $10.10, down from $10.60 to $10.75, primarily due to expenses related to acquisitions, including a $13 billion purchase of cardiac device company Shockwave.

Challenges in Medical Devices and Talc Lawsuits

Sales in J&J’s medical technology segment grew by 2.2% to $7.96 billion but missed analysts' expectations of $8.17 billion. This shortfall was attributed to decreased sales of surgical devices due to competition, supply constraints, and reduced demand for bariatric procedures. James Harlow of Novare Capital Management emphasized the need for faster growth within the MedTech sector.

The company's vision business and operations in China also underperformed. Wolk highlighted the volatile market conditions in China and noted that negotiations over bulk purchasing of medical devices could pose a short-term challenge for the company.

Investor sentiment has also been tempered by ongoing lawsuits related to J&J’s talc products, with thousands of claims alleging the products caused cancer. A key decision is anticipated soon regarding the company's third attempt at a bankruptcy strategy for a subsidiary to limit liability and set up a fund for victims. Receiving endorsements from major law firms representing claimants has been a recent development.

Harlow mentioned that resolving the talc litigation and gaining clarity on Stelara’s sales prospects are essential for a sustained uplift in the company's stock performance.